Company Profile (AI Text) Name: Nucleus Canonical URL: https://wefunder.com/nucleus Updated at: 2026-06-02T05:01:14Z Tagline: A venture studio for psychedelics Elevator pitch: We own and operate assets that connect people with the psychedelics industry. Key claims: - Total raised on Wefunder: 517249 | citation: https://wefunder.com/nucleus#claim-total-raised - Total investors: 130 | citation: https://wefunder.com/nucleus#claim-total-investors Verified facts: - Total raised on Wefunder: 517249 | observed_at: 2026-06-02T05:01:14Z | expires_at: 2026-06-03T05:01:14Z - Total investors: 130 | observed_at: 2026-06-02T05:01:14Z | expires_at: 2026-06-03T05:01:14Z Computed metrics: - total_amount_raised: 517249 - total_investors: 130 - team_size: 6 - featured_investor_count: 1 - faq_count: 5 - recent_post_count: 10 Quick facts: - ๐Ÿค A founding team of serial entrepreneurs with multiple exits | citation: https://wefunder.com/nucleus#claim-fact-1 - ๐Ÿ’ฐ Backed by one of the largest VC firms in the psychedelics industry, Iter Investments | citation: https://wefunder.com/nucleus#claim-fact-2 - ๐Ÿ”ฅWell-positioned for the imminent adoption of psychedelic-assisted therapy | citation: https://wefunder.com/nucleus#claim-fact-3 - ๐Ÿ“ˆA growing audience of approximately 50,000 subscribers, users, and followers | citation: https://wefunder.com/nucleus#claim-fact-4 - ๐Ÿ’ธA sales pipeline of approximately 200 psychedelic companies | citation: https://wefunder.com/nucleus#claim-fact-5 - ๐Ÿ‘€An expanding content network exceeding 100,000 pageviews per month | citation: https://wefunder.com/nucleus#claim-fact-6 - ๐Ÿš€A growing network of approximately 3,000 care practitioners | citation: https://wefunder.com/nucleus#claim-fact-7 - โšก๏ธA developing portfolio of 8 brands, with more on the way | citation: https://wefunder.com/nucleus#claim-fact-8 FAQ: - Q: How do you envision investors getting a return on their investment? Do you hope to IPO? Have some type of exit? A: Hey @MN! Thanks for the question! With our current structure as a venture studio, I have two answers for you. 1. Our Individual Brands Can Be Acquired: Nucleus owns and operates the brands it creates until it doesn't have to anymore. That's when they can spin off on their own, raise their own capital, and establish many liquidation events as they grow on their own. Multiply this process across several successful brands, and Nucleus can unearth a great deal of return for investors along the wa... - Q: Would like to invest, but also would like to use that investment to get my foot in the door for a position at this company. Is there room on the team? A: Hey James, Thanks for the question. As soon as we close this crowdfunding campaign, we will certainly be filling a handful of full-time roles spanning marketing, development, sales, and operations. At that point in time, we'll encourage you to submit your application for the role that's most appropriate for you and your skillset(s). Until then, what better way to stay informed on these future opportunities than to play a role as an active investor in the company? I look forward to welcoming y... - Q: How Nucleus is earning money or generating revenue? A: Hey Manu, Thank you for the question! Please see above to the response to your question. I hope that helps. Please let us know if you have any further questions. - Q: I went through company's profile but unable to understand how this company is earning money or generating revenue ? A: Hey Manu, Thank you for the question! Nucleus is the holding company developing the individual brands that you see laid out in the overview. All revenue that is being generated is coming from those companies. Neuly generates revenue from data subscriptions. Psychedelic Invest earns revenue from paid sponsorships, affiliate sales, and PRO subscribers. Psyrise, which is our fastest-growing asset, is a marketing platform that generates revenue by creating patient and user demand for ketamine cli... - Q: 1) How big is the global psychedelics market and how much of it do you think you can capture? 2) Is the plan to scale each company in the Nucleus portfolio into a unicorn? A: Hey Kevin, Thanks for the questions. 1. Currently valued at half a million, the psychedelics industry is forecasted to reach $8-$11 million by 2028. The sector is growing rapidly and Nucleus will continue to be well-positioned to offer data, marketing, entertainment, and other ancillary services as demand expands. 2. Nucleus has ambitions to establish each individual entity as its own brand servicing the industry accordingly. In that way, every company is structured to scale individually with... Recent posts: - Nucleus: 2025 Recap (2025-12-28T22:05:22Z) https://wefunder.com/feed/236626 - Nucleus: Q3 Recap (2024-10-18T08:00:47Z) https://wefunder.com/feed/176821 - Nucleus: Q2 Update (2024-07-12T16:39:01Z) https://wefunder.com/feed/174540 - Nucleus: April & May Update (2024-06-11T21:07:18Z) https://wefunder.com/feed/173961 - Nucleus: A Review of Q1 2024 (2024-04-12T19:01:07Z) https://wefunder.com/feed/172456 - Nucleus: Q1 2024 Update (2024-03-15T04:51:31Z) https://wefunder.com/feed/171537 - Q4 Review/2023 in Review (2024-01-26T20:12:10Z) https://wefunder.com/feed/169809 - November Review (2023-12-05T22:19:05Z) https://wefunder.com/feed/169082 - October in Review (2023-11-17T03:52:05Z) https://wefunder.com/feed/168674 - Q3 Recap (2023-10-06T18:56:35Z) https://wefunder.com/feed/167646